iBio reports positive preclinical data for IBIO-610 obesity candidate

• iBio (NASDAQ:IBIO) reported preclinical obese non-human primate data for IBIO-610, showing a single dose reduced active Activin E by 98% at week 4 and 97% at week 8.
• Combined with semaglutide, IBIO-610 increased visceral and total fat loss and reduced lean mass loss by 73% versus semaglutide alone.
• The results suggest fat-selective weight loss potential and infrequent dosing for IBIO-610.

iBio (NASDAQ:IBIO) reported preclinical obese non-human primate data for IBIO-610, a potential first-in-class Activin E antibody for obesity.

A single dose reduced active Activin E by 98% at week 4 and 97% at week 8, with levels below assay limits.

Combined with semaglutide, IBIO-610 increased visceral and total fat loss and reduced lean mass loss by 73% versus semaglutide alone.

The results suggest fat-selective weight loss potential and infrequent dosing.

Full results will be presented at the 2026 EASD Annual Meeting in Milan.

iBio is advancing IBIO-610 as part of its pipeline focused on innovative antibody therapeutics for metabolic disorders.

The company continues to leverage its AI-driven drug discovery platform to develop candidates with potential advantages in safety and efficacy.